# Five Peptides, One Question: What Actually Crossed the Finish Line? > Avant Peptides — Research Peptide Fundamentals — Avant Peptides is a plain-English orientation to Research Peptide Fundamentals research peptides — semaglutide, tirzepatide, tesamorelin, BPC-157, and PT-141 — what each one is, how it works, and what the literature actually shows. **RESEARCH PEPTIDE FUNDAMENTALS** A plain-English orientation to five of the most-discussed research peptides — semaglutide, tirzepatide, tesamorelin, BPC-157, and PT-141 — read through the translational gap: which ones cleared the bar to become approved medicine, which stalled at the bench, and why the distance between the two matters. ### [Semaglutide](/semaglutide) ![Semaglutide research illustration](images/semaglutide.webp) A GLP-1 receptor agonist that made the full crossing — approved for diabetes, weight management, cardiovascular risk reduction, and liver disease, backed by some of the largest trial programs in peptide medicine. ### [Tirzepatide](/tirzepatide) ![Tirzepatide research illustration](images/tirzepatide.webp) A dual GIP/GLP-1 agonist that beat semaglutide head-to-head and cleared its own path to approval across diabetes, weight management, and sleep apnea. ### [Tesamorelin](/tesamorelin) ![Tesamorelin research illustration](images/tesamorelin.webp) A GHRH analogue approved for one narrow job — reducing visceral fat in HIV-associated lipodystrophy — and a clear example of how an approval can be real but narrow. ### [BPC-157](/bpc-157) ![BPC-157 research illustration](images/bpc-157.webp) A gastric-derived peptide with a large, mostly rodent evidence base and only a handful of small human pilot studies — the clearest case on this site of a peptide still stuck at the bench. ### [PT-141](/pt-141) ![PT-141 research illustration](images/pt-141.webp) Bremelanotide, a melanocortin-receptor peptide approved for one specific diagnosis in one specific population, widely discussed for uses well outside that label. ## The short version Every peptide on this site started in the same place: a laboratory bench, a hypothesis, and early experiments. What happened after that is where the stories split. Some, like semaglutide, went on to become extensively studied medicines with large human outcome trials [2][3]. Others, like BPC-157, are still mostly rodent data with only a few human pilot studies behind them [17][18]. A few, like tesamorelin and PT-141, made it to approval but only for one narrow, specific use — not the broader uses people often discuss them for [13][24]. We call this gap between *promising in a lab animal* and *proven and approved in humans* the **translational gap**. It is not a technicality. It is the single most useful lens for reading anything written about a research peptide, because the size of that gap shows how much weight the evidence can actually carry. This site walks through five peptides with five different positions on that spectrum, cites the studies behind its research claims, and leaves no ambiguity about which stage a compound has reached. Nothing here is medical advice, and nothing here recommends a dose for a person to take. We report what was studied, in which population, and what the researchers found. ## Why the translational gap matters A peptide that "works" in a mouse has cleared the lowest bar in a very long process. Getting from there to an approved human medicine typically means dose-finding studies, safety trials in progressively larger groups of people, and — for the compounds that make it all the way — a regulatory review of the full data package. Along that path, plenty of promising molecules stall: the effect seen in animals does not replicate in people, the side-effect profile is worse than expected, or development simply moves toward another candidate. Semaglutide and tirzepatide sit at the far end of that path. Both have large human trial programs, including cardiovascular, kidney, weight, and blood-sugar outcomes [1][2][3][4][10][11]. Tesamorelin and PT-141 also reached approval, but each for a single, narrower use — tesamorelin for one form of fat redistribution in one patient population, PT-141 for one diagnosis in one population [13][24]. BPC-157 has not reached that stage: the latest review found only a handful of small human pilot studies, while most published work remains rodent or cell-culture research [18]. Knowing where a compound sits on this spectrum changes how any claim about it should be read — including the claims on this site. ## What are research peptides? Peptides are short chains of amino acids — smaller cousins of the proteins the human body makes and uses constantly. The five compounds covered here were each built by taking a natural signal the body already produces, or something structurally close to one, and adjusting it to last longer or bind more precisely to a receptor. Semaglutide and tirzepatide are engineered versions of gut-hormone signals involved in appetite and blood sugar. Tesamorelin is an engineered version of the signal that tells the pituitary gland to release growth hormone. BPC-157 is derived from a sequence found in gastric juice. PT-141 is built from the hormone family involved in skin pigmentation and, separately, sexual-desire circuits in the brain. Some of these compounds are approved prescription medicines, dispensed under medical supervision for the specific conditions studied. Others are sold by research suppliers labeled "for laboratory research use only" — material that sits outside the pharmaceutical approval system, with no independent verification of purity or contents. This site treats those categories differently and states plainly on every compound page which category applies. --- Avant Peptides independently maps the distance from peptide benchwork to approved medicine; it is an editorial digest, not a clinic, pharmacy, or prescription.